Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men

American Journal of Cardiology

Volumn 80, Issue 8, 1997, Pages 1021-1024

  Blumenthal, Roger S ^a   Heldman, Alan W ^b   Brinker, Jeffrey A ^b   Resar, Jon R ^b   Coombs, Vicki J ^b   Gloth, Sean T ^b   Gerstenblith, Gary ^b   Reis, Steven E ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ESTROGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; ESTROGEN ACTIVITY; ESTROGEN THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ACETYLCHOLINE; BLOOD PRESSURE; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ESTROGENS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED;

EID: 0030704707     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00596-1     Document Type: Article

References (23)

1. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attentuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
2. Collins P, Rosano GMC, Sarrel P, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17 β-estradiol attentuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
3. Washburn SA, Adams MR, Clarkson TB, Adelman SJ. A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat. Am J Obst Gynecol 1993;169:251-256.
4. Washburn SA, Honore EK, Cline JM, Helman M, Wagner JD, Adelman SJ, Clarkson TJ. Effects of 17 α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys. Am J Obst Gynecol 1996;175:341-351.
5. Doucette JW, Cori D, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899-1911.
6. Reis SE, Resar JR, Blumenthal RS, Gloth ST, Gerstenblith G, Brinker JA. Effects of aging on the modulation of coronary flow by endothelium-independent vasodilators in postmenopausal women. Cardiol in the Elderly 1995;3:43-51.
7. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilatation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995; 26:807-814,
8. Williams JK, Adams MR, Klopfenstein HB. Estrogen modulates responses to atherosclerotic coronary arteries. Circulation 1990;81:1680-1687.
9. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-457.
10. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-1761.
11. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-2451.
12. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Effects of estrogen therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-268.
13. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelium-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:751-752.
14. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-941.
15. Blumenthal RS, Brinker JA, Resar JR, Gloth ST, Zacur HA, Coombs VJ, Gerstenblith G, Reis SE. Chronic estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women. Am Heart J 1997;133:323-328.
16. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995;92:5-8.
17. The Coronary Drug Project Research Group. The coronary drug project: initial findings leading to modifications of its research protocol. JAMA 1970;214: 1303-1313.
18. The Coronary Drug Project Research Group. The coronary drug project: findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 1973;226:652-657.
19. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-136.
20. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspectives 1995;8:531-539.
21. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan DJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY13948 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-69.
22. Cline JM, Obasanjo IO, Pasechold JL, Adams MR, Anthony MS. Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal Macaques. Fert Steril 1996;65:1031-1035.
23. Anderson JW, Johnstone BM, Cooke-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-282.